Semaglutide and Thyroid Nodules: What Patients Should Know

The Black Box Warning Explained

Every semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) prescription comes with a black box warning about thyroid C-cell tumors. This is the most serious type of FDA warning. It understandably scares patients.

But the context behind this warning matters, and most providers do not explain it adequately. Let me break it down.

What the Animal Studies Found

In preclinical studies, rats given semaglutide at doses 2-20 times the maximum human dose developed medullary thyroid carcinoma (MTC) at significantly higher rates than control animals. This occurred consistently across all tested GLP-1 receptor agonists — liraglutide, semaglutide, tirzepatide, and dulaglutide.

The mechanism: rodent thyroid C-cells have high concentrations of GLP-1 receptors. When these receptors are chronically stimulated by GLP-1 medications, the cells proliferate and can become malignant.

This finding triggered the mandatory black box warning on all GLP-1 medications.

Why Humans Are Probably Different

Species Difference in GLP-1 Receptor Expression

Here is the critical distinction: human thyroid C-cells have very low expression of GLP-1 receptors compared to rodent C-cells. Multiple studies examining human thyroid tissue have found minimal to negligible GLP-1 receptor expression on C-cells.

This means the mechanism that drives thyroid cancer in rats may not apply to humans — the target receptor is barely present in human thyroid tissue.

Human Data

After more than 15 years of widespread GLP-1 medication use globally (starting with exenatide in 2005, liraglutide in 2010, semaglutide in 2017), the human evidence shows:

• No signal of increased MTC in pharmacovigilance databases beyond baseline rates
• The SUSTAIN and STEP trials showed no thyroid cancer cases attributable to semaglutide
• The SELECT trial (17,600+ patients followed for over 3 years) showed no increase in thyroid malignancies
• A 2023 meta-analysis in Diabetes Care pooling GLP-1 trials found no statistically significant increase in thyroid cancer

Calcitonin levels (the biomarker for C-cell activity) remain stable in humans on GLP-1 medications, unlike the dramatic elevations seen in rodents.

Why the Warning Remains

The FDA maintains the black box warning because:

• They cannot ethically run a controlled trial giving humans high-dose GLP-1 for decades to definitively rule out risk
• The animal signal is consistent and dose-dependent
• MTC is slow-growing — decades might be needed to detect a signal in humans
• Precautionary principle applies for a non-life-threatening condition (obesity)

The warning is appropriate from a regulatory standpoint. But it does not mean semaglutide causes thyroid cancer in humans — it means we cannot prove it does not.

Who Should Be Cautious

Despite the low human risk, certain patients should avoid GLP-1 medications or use them with heightened monitoring:

Absolute Contraindications

• Personal history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — genetic condition with very high MTC risk. MEN2 patients have RET proto-oncogene mutations.

Relative Cautions

• Family history of MTC — particularly first-degree relatives. Consider genetic testing for RET mutations before starting.
• Existing thyroid nodules — should be evaluated with ultrasound and possibly fine-needle aspiration before starting GLP-1 medications. If benign, treatment can proceed with monitoring.
• Elevated baseline calcitonin — calcitonin above 50 pg/mL warrants further workup before starting GLP-1 therapy.

What About Common Thyroid Nodules?

Thyroid nodules are extremely common — present in 50-70% of adults when screened by ultrasound. The vast majority are benign. Having a thyroid nodule does NOT automatically disqualify you from GLP-1 medication.

The approach:

1. If you have known thyroid nodules, ensure they have been appropriately evaluated (ultrasound characteristics, FNA biopsy if indicated)
2. If nodules are confirmed benign (Bethesda I-II), GLP-1 medications can be used
3. If nodules are suspicious or indeterminate, resolve the thyroid workup first
4. Routine thyroid ultrasound screening is NOT recommended before starting GLP-1 medications in patients without risk factors

Monitoring While on Treatment

For most patients on GLP-1 medications, no specific thyroid monitoring is required beyond standard care.

However, report these symptoms to your provider:

• A new lump or swelling in the front of your neck
• Difficulty swallowing
• Persistent hoarseness
• Unexplained neck pain

These symptoms warrant thyroid evaluation regardless of GLP-1 use.

For patients with risk factors (family history of MTC, known thyroid nodules):

• Consider baseline calcitonin level
• Periodic thyroid examination (palpation)
• Low threshold for ultrasound if any new symptoms or findings

Perspective

Medullary thyroid carcinoma accounts for only 3-5% of all thyroid cancers. Thyroid cancer itself is relatively uncommon (approximately 44,000 new cases per year in the US). MTC specifically affects roughly 1,000-2,000 Americans annually.

Meanwhile, obesity contributes to over 200,000 deaths per year and is a risk factor for at least 13 types of cancer — including thyroid cancer itself.

The risk-benefit calculation for most patients strongly favors GLP-1 treatment. The theoretical, undemonstrated thyroid risk is outweighed by the known, demonstrated benefits of meaningful weight loss.

The Bottom Line

The thyroid warning on GLP-1 medications reflects rodent data that has not materialized in over 15 years of human use. It is not nothing — but for the vast majority of patients without personal or family history of MTC, it should not be the reason you avoid treatment that could significantly improve your health.

At Coral, we screen for MTC risk factors before prescribing GLP-1 medications and monitor appropriately. [Start your visit](/start) and let us evaluate whether these medications are safe for you.